About
About Cymab
Cymab develops a novel class of antibodies for patients with non-immunogenic tumors. Our Targeted Immune Stimulation (TIMS) approach directs the body’s own interferon gamma (IFNγ) to the tumor microenvironment and ignites anti-cancer immunity.
Invitation to tender
Development and production of subcutaneous antibody formulation
Suppliers with expertise in developing and producing antibodies at GLP/GMP quality and track record in developing and assessing liquid formulations for subcutaneous administration.
Read tender details
Tender
Tender details
Development and production in GLP-compliant environment of high-concentration liquid injectable formulation of CYM-001 multispecific antibody.
- SUBMISSION DEADLINE
- 28 February 2027
- REFERENCE
- Cymab ESS01
- ISSUED BY
- Cymab HK Limited
- DATE PUBLISHED
- 31-October-2026
- WHO MAY TENDER
- Companies with legal entity in Hong Kong
- HOW TO SUBMIT
- Email submission
- ENQUIRIES
- Mads Holmegaard, mg@cymab.bio